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Recurrence of focal segmental glomerulosclerosis (FSGS) after renal transplantation is a complication that often leads to graft
loss. There is no consensus on the optimal treatment of recurrent FSGS. Rituximab, a monoclonal antibody to CD20, may be
a useful treatment of this complication. Methods. We report four pediatric cases of recurrent FSGS treated with rituximab and
plasmapheresis. Results. Four children (2M/2F), age 15.3 ± 2.6, with recurrent FSGS posttransplant were identiﬁed. Four doses of
rituximab were administered 171 ± 180 days posttransplant and 114 ± 169 days after the start of plasmapheresis. Three children
responded with complete remission, one of whom relapsed after four months. One child had a partial response with a decrease
in proteinuria that was not sustained. No adverse side eﬀects were reported during treatment or followup (mean 22.5 months).
Conclusions.Rituximabisa safeandwell-tolerated ancillarytreatment forrecurrent FSGS in pediatric patients inconjunctionwith
plasmapheresis.
1.Introduction
Recurrence of focal segmental glomerulosclerosis (FSGS)
occurs in 25–53% of patients with this glomerulopathy who
receive a kidney transplant and in over 80% of patients
receiving subsequent transplants after previous recurrence
[1–6]. Recurrent disease often leads to graft loss [7]. The risk
of recurrence appears to be higher in pediatric kidney trans-
plant recipients with FSGS compared to adult patients [4, 8].
FSGS can recur as early as a few hours after transplant
and as late as two years post-transplant [7]. The pathogen-
esis of this entity is not completely understood; however,
glomerular injury is thought to be mediated by a low-mo-
lecular weight circulating permeability factor that aﬀects
podocyte function or by loss of an inhibitor of this factor.
Plasmapheresis (PP) has been shown to decrease activity
of the permeability factor in the circulation and to induce
remission of recurrent FSGS, thus supporting a key role of
thepermeabilityfactor inthepathogenesisofthis disease[2].
There is no consensus onthe optimal treatment of recur-
rent FSGS due to the lack of controlled studies. Several case
seriesreportcompleteremissionratesof50–67%inpediatric
transplant recipients treated with PP [9–11]. Other thera-
pies including administration of high doses of calcineurin
inhibitors, cyclophosphamide and angiotensin converting
enzyme inhibitors have been tried with variable results.
There are scattered reports that rituximab, a monoclonal
antibody to CD20, may be useful for the treatment of this
complication.
We report our experience of treatment with rituximab
and PP in an unselected group of pediatric renal transplant
recipients with recurrent FSGS at a single center.
2.Materialsand Methods
Medical records were retrospectively reviewed to identify
childrenwho receiveda kidney transplant atthe MountSinai
Medical Center and who developed recurrence of FSGS2 Journal of Transplantation
that was treated with rituximab during the past 2 years.
Recurrence of FSGS was diagnosed based on the presence
of nephrotic-range proteinuria in the absence of another
causeandadeclineintheserumalbuminconcentration.Pro-
teinuria was measured by the protein (mg/dL) to creatinine
(mg/dL) ratio (UP/C) in a ﬁrst morning urine sample with
nephrotic-range proteinuria deﬁned as >2.0.
Once recurrence of FSGS was documented, PP was pre-
scribed as clinically indicated. Rituximab was administered
intravenously at a dose of 375mg/m2 once a week for four
weeks. The initial dose of rituximab was administered
in the inpatient setting. The infusion was started at a
rate of 50mg/hour and was increased by 50mg/hour in-
crements as tolerated every 30 minutes, to a maximum
rate of 400mg/hour. Subsequent infusions were started at
100mg/hour and increased by 100mg/hour increments
as tolerated every 30 minutes, to a maximum rate of
400mg/hour. All patients were premedicated with acet-
aminophen and diphenhydramine prior to each dose of
rituximab. The response to therapy was measured by serial
UP/C ratios in the ﬁrst morning urine sample.
3.Results
A total of four children (two males and two females) age
15.3 ± 2.6 (range 13–18), were identiﬁed with recurrent
FSGS and who were treated with rituximab. All children
had intact native kidneys. They all received deceased donor
allografts and an immunosuppressive regimen that con-
sisted of thymoglobulin induction, prednisone, tacrolimus,
and mycophenolate mofetil. Renal biopsy conﬁrming FSGS
recurrence was performed in three children (all but Case 2).
PP was initiated 58 ± 106 days post-transplant (range 2–217
days). Rituximab was administered 171 ± 180 days (range
10–395 days) post-transplant and 114 ± 169 days (range 8–
389 days) after the start of PP. Two patients (Cases 1 and
2) were treated with PP and rituximab concurrently within
two weeks post-transplant. After a mean follow-up period of
22.5 months after rituximab, three children responded with
complete remission (Cases 2, 3 and 4), but one (Case 4)
relapsed within four months of remission. He received
another dose of rituximab and currently remains on PP
with improvement in proteinuria. One child (Case 1) had
a partial response with a decrease in proteinuria, but it was
not maintained. However, her kidney function has remained
normal despite persistent nephrotic range proteinuria. No
adverse side eﬀects of treatment were reported. Patient
characteristics, management, and outcome of the four cases
are shown in Table 1.
Case 1. This female patient was diagnosed with biopsy-
proven FSGS at the age of ﬁve years old. She progressed to
end stage kidney disease within seven months and was
started on hemodialysis. She received a deceased donor
kidney transplant at the age of eight with immediate
recurrence of the disease in the allograft. Despite seven
months of PP, she eventually lost the allograft and was
placed on peritoneal dialysis. Due to high sensitization to
HLA-speciﬁc antibodies, she underwent a desensitization
Table 1: Clinical features of cases of pediatric recurrent FSGS.
Case 1 Case 2 Case 3 Case 4
Age at transplant 13 13 17 18
Sex FM F M
Ethnicity Black Asian Hispanic Hispanic
Donor DD DD DD DD
PP start (days posttxp) 2 5 6 217
PP duration (days) 540 93 485 527
Rituximab start
(days posttxp)
10 14 395 267
Urine UP/C Pre-PP 5.8 25–44 11 20
Urine UP/C nadir 0.8 0.1 0.2 0.18
Urine UP/C current 1.8 0.1 0.2 10.7
Current eGFR
(mL/min/1.73m2)
113 127 88 106
Follow-up
postrituximab
(months)
23 22 24 22
Current PP No No No Yes
F: female; M: male; DD: deceased donor; PP: plasmapheresis; UP/C:u r i n e
protein to creatinine ratio.
protocol with intravenous immunoglobulin. At age 13, she
received a deceased donor kidney transplant and again had
immediate recurrence of proteinuria. Laboratory ﬁndings
on postoperative day 2 showed UP/C 5.8, serum albumin
2mg/dL, and serum creatinine 0.7mg/dL. She was started
on PP on postoperative day #2 and received the ﬁrst dose
of rituximab on postoperative day #10. A renal biopsy
performed three months post-transplant showed extensive
podocyte foot eﬀacement suggestive of recurrence of FSGS.
FSGS was conﬁrmed on biopsy performed six months post-
transplant with 20/25glomerulishowing segmentalsclerosis,
varying from mild to global, with moderate to severe patchy
interstitial ﬁbrosis. She attained a partial response with a
UP/C nadirof0.8thatwasnotsustained.PPwasdiscontinued
after 18 months. She currently has a UP/C r a t i oo f1 . 8 ,b u ti s
clinically well with serum creatinine 0.65mg/dL and serum
albumin 3.1mg/dL.
Case 2. This male patient was diagnosed with steroid resis-
tant nephrotic syndrome at the age of 10 years old, which
was later conﬁrmed to be FSGS on biopsy. He was treated
with cyclosporine and ACE inhibitor for six months with
no response and progressed to end stage kidney disease
and hemodialysis within three years. At age 13, he received
a deceased donor kidney transplant. He had immediate
recurrence of proteinuria with laboratory data of UP/C 25–
44, serum albumin 2.1mg/dL, and serum creatinine 1.1. PP
wasstartedonpostoperativeday5,andhereceivedrituximab
on postoperative day 14. He demonstrated good response
to treatment within one month. Laboratory data revealed
UP/C 0.19, serum creatinine 0.9mg/dL, and serum albumin
4.3mg/dL. PP was discontinued 3 months post-transplant
due to a central line infection. His current status 22 months
post-transplant is UP/C 0.1, serum creatinine 0.75mg/dL,Journal of Transplantation 3
andserumalbumin4.2mg/dL.Heismaintainedonlisinopril
10mg daily.
Case 3. This female patient presented with nephrotic syn-
drome at 18 months of age. She was initially steroid sen-
sitive and then became steroid resistant. Renal biopsy con-
ﬁrmed FSGS. She progressed to ESRD and was started
on hemodialysis at age 14. She received a deceased donor
kidney transplant at age 16. Nephrotic syndrome developed
immediately post-transplant, and a transplant biopsy done
on post-transplant day six showed extensive eﬀacement of
foot processes without focal sclerosis of the glomeruli (14
glomeruli). She was started on PP. The patient was PP
dependent and received rituximab one year later. She went
into complete remission and was weaned oﬀ PP. Currently
24 months post-rituximab, she has a Pr/Cr of 0.2 and serum
creatinine 1.0–1.3mg/dL.
Case 4. This young man presented with steroid resistant
nephrotic syndrome at the age of ﬁve years old. FSGS
was diagnosed on biopsy. Over a 12-year period, he was
treated with multiple medications in an eﬀort to induce
remission. At age 17, his kidney function declined and he
was placed on hemodialysis. After two months of dialysis,
he received a deceased donor kidney transplant. The UP/C
ratio ranged 7–15.3 in the ﬁrst post-transplant month,
thought to stem from his native kidneys. Over the next two
months, his UP/C decreased to a nadir of 0.8 and serum
albumin increased from 2.5 to 4mg/dL. His UP/C gradually
began to increase over the following months up to 9.7,
and serum albumin declined to 2.3mg/dL. A biopsy of
the allograft was performed seven months post-transplant.
Results showed moderate to extensive eﬀacement of the
podocyte foot processes with absence of focal sclerosis of the
glomeruli. PP was initiated three times a week with poor
response, maximum UP/C 26. The ﬁrst dose of rituximab was
administered 50 days after the start of PP. UP/C decreased
from 17.5 at the start of rituximab to 3.7 after the fourth
dose. Nine months after the start of rituximab, the patient
attained complete remission of proteinuria, UP/C 0.18, on
once a month PP, which was sustained for four months.
Thirteenmonthsafterthestartofrituximab,herelapsedwith
nephrotic range proteinuria, and PP therapy was intensiﬁed.
There was no improvement in proteinuria overthe following
six months, max Pr/Cr 28. He received another dose of
rituximab, 1 gram. B cell depletion was conﬁrmed after the
single dose and no further doses were given. Two months
post-rituximab, the proteinuria improved, Pr/Cr 2.6 and PP
were continued twice weekly.
4.Discussion
In this retrospective chart review, we found that three out of
four cases (75%) with recurrent FSGS post-transplantation
had a favorable response to the combination of rituximab
and plasmapheresis with complete remission. One child
who attained complete remission relapsed and subsequently
received another dose of rituximab with improvement in
proteinuria. One child demonstrated a partial remission of
proteinuria, but it was not sustained. eGFR was stable in all
patients, even in the child with persistent nephrotic-range
proteinuria (Case 1). There were no adverse events related
to rituximab such as infection or malignancy over the entire
follow-up period in all four cases.
Rituximabis achimericmonoclonalantibody against the
CD-20 antigen which results in depletion of B-lymphocytes.
Its beneﬁcial role in the treatment of nephrotic syndrome
was discovered incidentally during treatment of idiopathic
thrombocytopenic pupura in a patient with nephrotic syn-
drome[12]andintreatment ofpost-transplant lymphprolif-
erative disorder in a pediatric renal transplant recipient with
FSGS recurrence [13]. Since then, rituximab treatment for
recurrent FSGS has been reported with mixed results. Yabu
et al. described failure of rituximab used as a single agent
in four adult transplant recipients [14]. However, in seven
adults,thecombinedtreatment ofPPand rituximabinduced
complete or partial remission in 71.4% [15].
Pediatric patients may respond more favorably to ritux-
imab [4]. A review of reported cases demonstrated a positive
response to rituximab for the treatment of recurrent FSGS
in 80% of pediatric transplant patients (Table 2)[ 4, 13, 16–
21]. Of 15 cases (age 10.4 ± 4.5), complete remission was
achievedin10(67%)andpartial remission in2(13%).Three
cases showed no response to treatment. In three cases, PP
was discontinued prior to rituximab, and PP was not used
at all in one case. Of note, although the average age (15.3 ±
2.6) in our series is higher than these reported cases, the
outcomes are similar. A multicenter case series by Prytula
et al. was not included in the review because information
was obtained via survey, and repeat reporting of cases could
not be ascertained. In this series of 15 pediatric transplant
patients, 40% attained complete remission, 27% attained
partial remission and 33% hadn or e s p o n s et or i t u x i m a b
[22]. Data on PP was not available.
Our series is unique in that it is the largest pediatric
cohort of recurrence of FSGS with deceased donor allografts
treated at a single center that has been described in the
literature. Hickson et al. described a favorable outcome with
rituximab in four pediatric patients who received living
related donor allografts [4].
Our study is limited by the lack of consistent B cell mon-
itoring in all cases. The child in Case 4 attained remission
9 months after an initial course of rituximab and relapsed
after 13 months. The timing of B cell depletion and repletion
in relation to these events is not known. B cell depletion
was documented after a second round of rituximab, which
was associated with reduction in proteinuria. However, as in
other reported cases [4] ,t h er e s p o n s et or i t u x i m a bm a yb e
delayedbyseveralmonths,andextendedfollowupisrequired
to determine responsiveness.
Because of the variable time of initiation of rituximab in
relation to PP, we cannot deﬁnitively attribute the successful
outcome to a particular treatment. Rituximab is often used
as rescue therapy after a trial of PP had failed to induce
remission of proteinuria. Rituximab was given concurrently
at the start of PP in two of our cases. Earlier administration
of rituximab in conjunction with plasmapheresis may in-
creaseeﬃcacy;however,thepotentialbeneﬁtsrequirefurther4 Journal of Transplantation
Table 2: Summary of the literature on use of rituximab in pediatric recurrent FSGS.
Age Sex Donor PP start
(days posttxp)
Rituximab start
(days posttxp) Response Notes
Nozu et al. [13] 12 M LRD N/A 186 CR No PP given
Pescovitz et al. [16] 7 M DD 14 155 PR PP stopped 3 months prior to
rituximab
Marks and McGraw [17] 6 M DD 20 60 NR PP stopped 3 months prior to
rituximab
10 M DD 4 294 NR Rituximab 750mg/m2 × 2
Apeland and Hartmann [18] 18 M DD 7 403 CR
Bayrakci et al. [19]1 4 M L R D −54 C R P P s t a r t e d p r e - t x p
Dello Strologo et al. [20]
9 — — 3629 3659 CR
13 — — 90 328 PR
7— — 2 1 2 C R
12 — — 43 65 NR
Hickson et al. [4]
19 F LRD 2 12 CR
6ML R D −87 C R P P s t a r t e d p r e - t x p
13 M LRD −5 928 CR PP started pre-txp
5ML R D −7 63 CR PP started pre-txp
Grenda et al. [21] 5 M DD 2 90 CR PP stopped prior to rituximab
M: male; F: female; LRD: living related donor; DD: deceased donor; CR: complete response; PR: partial response; NR: no response; PP plasmapheresis.
∗Does not include cases from Prytula et al. [22].
investigation. It is important to note that even in the patients
who had persistent proteinuria, the rituximab may have had
a beneﬁcial eﬀect to stabilize GFR because one might have
anticipated progressive decline in kidney function in these
cases.
5.Conclusion
Rituximab is a safe and well-tolerated ancillary treatment
for recurrent FSGS in pediatric patients in conjunction with
PP. Multicenter clinical trials are needed to determine the
eﬃcacy of rituximab in this setting and to deﬁne the optimal
timing, dose, and duration of this treatment.
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